English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The FDA has approved tumor treating fields (Optune) to treat glioblastoma (GBM) and unresectable mesothelioma. Optune uses scalp electrodes to pass a strong alternating electric field through the head, slowing GBM growth. We have recently developed and tested a novel device that uses an oscillating magnetic field (OMF) generated by rotating magnets to treat GBM. Our first GBM patient had a recurrent GBM with leptomeningeal spread. A custom-made Oncomagnetic device consisting of a multi-sport helmet with three OMF generators called oncoscillators, was worn by the patient at home. Changes in the brain and GBM tumor metabolism were examined using in vivo1H MRS on a 7T Siemens MRI scanner. 1H MRS data of the “tumor” and “non-tumor” regions during OMF treatment was obtained using sLASER pulse sequences. Both non–tumor and tumor regions showed the most common brain metabolites – myo-inositol, creatine, choline, glutamine/glutamate, and N-acetyl aspartate (NAA). 30 days after initiation of treatment, choline, creatine and NAA levels in the shrunken tumor region had collapsed. The tumor region displayed broad proton signals centered at 1.30 ppm and 0.88 ppm. These peaks have been observed following successful brain tumor radiation therapy and have been attributed to the presence of mobile lipids due to tumor necrosis. Our in vitro experiments suggest OMF-induced damage to mitochondria and elevated levels of reactive oxygen species, leading to cancer cell death via apoptosis and necrosis. We propose that loss of choline and elevation of lipid levels may be used as a metabolite ‘fingerprint’ to noninvasively assess the Oncomagnetic treatment response. This powerful new treatment holds great promise for treatment of patients with GBM, and produces rapid changes in brain chemistry during treatment.

neuro-oncology

NIMG-48. USE OF MOBILE LIPIDS AS METABOLIC MARKERS FOR THE ASSESSMENT OF TREATMENT-INDUCED NECROSIS IN A RECURRENT GLIOBLASTOMA PATIENT TREATED WITH A NEW OSCILLATING MAGNETIC FIELD GENERATING DEVICE